slc47a1 Antibody

What is SLC47A1 and what cellular functions does it perform?

SLC47A1, also known as Multidrug And Toxin Extrusion protein 1 (MATE1), is a membrane transporter belonging to the solute carrier family 47. It functions primarily as a cationic pump expressed in the kidneys, liver, and intestine. SLC47A1 plays a crucial role in the efflux of cationic endogenous substrates and xenobiotics from polarized epithelial cells at the apical membranes . The protein consists of 13 transmembrane helices with a long cytoplasmic tail, with specific cysteine and histidine residues critical for its functionality . Recent research has expanded our understanding of SLC47A1 beyond its traditional role as a membrane transporter, identifying its involvement in cancer progression and drug resistance mechanisms .

What are the key specifications of commercially available SLC47A1 antibodies?

SLC47A1 antibodies are available with various specifications depending on research needs. Based on current commercial offerings, researchers should consider the following parameters:

For optimal results, researchers should select antibodies that have been validated for their specific experimental system and application.

What are the recommended sample preparation methods for detecting SLC47A1 in different tissues?

Sample preparation methods vary based on the tissue source and experimental application. For Western blot detection of SLC47A1:

• Tissue homogenization: SLC47A1 is highly expressed in kidney, liver, and intestinal tissues, with expression also detected in brain and testis . Homogenize tissue in RIPA buffer supplemented with protease inhibitors.

• Membrane fraction enrichment: Since SLC47A1 is a membrane protein, enrichment of membrane fractions can improve detection. This can be achieved through differential centrifugation protocols.

• Protein loading: Load 20-50 μg of total protein per lane for optimal detection.

• Blocking conditions: Use 5% non-fat milk or BSA in TBST for blocking membranes to reduce background.

Validation studies have successfully detected SLC47A1 in rat kidney, mouse brain, and rat testis using anti-SLC47A1 antibodies at 1:200 dilution . For immunohistochemistry, perfusion-fixed frozen brain sections have been used successfully with anti-SLC47A1 antibodies, revealing expression in pyramidal neurons of the parietal cortex .

How does SLC47A1 expression correlate with cancer progression and prognosis?

Recent studies have established significant correlations between SLC47A1 expression and cancer progression:

• Glioma malignancy: High SLC47A1 expression is linked to increased malignancy and poor prognosis in glioma patients. In-silico analysis of public datasets revealed that high SLC47A1 expression correlates with reduced survival rates (TCGA - HR = 1.50; 95% CI = 1.40-1.60; P < 0.001; CGGA - HR = 1.60; 95% CI = 1.40-1.70; P < 0.001) .

• Stem cell characteristics: SLC47A1 is highly expressed in glioma stem cells (GSCs) compared to non-stem cell glioma cell lines and non-tumor cells. RT-qPCR analysis confirmed that SLC47A1 mRNA levels were significantly elevated in GSC cell lines (GSC11, GSC20, GSC23, and GSC267) compared to normal human astrocytes (NHA) and non-stem cell glioma cell lines (A172, A1207, LN229, and U87MG) .

• Therapeutic implications: Knockdown of SLC47A1 using shRNA reduces sphere-forming ability in GSCs and potentiates the effect of temozolomide (TMZ), suggesting potential therapeutic applications .

These findings indicate that SLC47A1 antibodies are valuable tools for assessing cancer progression and potentially identifying patients who might benefit from targeted therapies.

What methodological approaches can optimize SLC47A1 antibody specificity validation?

Ensuring antibody specificity is critical for reliable research outcomes. Recommended validation approaches include:

• Blocking peptide controls: Pre-incubate the SLC47A1 antibody with its specific blocking peptide (e.g., SLC47A1 Blocking Peptide #BLP-NT131) before application. This should substantially reduce or eliminate specific staining, as demonstrated in immunohistochemical staining of rat brain sections .

• Knockdown/knockout controls: Utilize siRNA/shRNA knockdown or CRISPR-Cas9 knockout models of SLC47A1 to confirm antibody specificity. This approach has been successfully employed in studies examining SLC47A1's role in glioma cells .

• Multiple antibody validation: Use different antibodies targeting distinct epitopes of SLC47A1 to confirm expression patterns.

• Cross-reactivity testing: Validate antibody performance across multiple species when conducting comparative studies. Available antibodies show reactivity with human, mouse, and rat samples, though sensitivity may vary .

• Western blot molecular weight verification: Confirm that detected bands align with the expected molecular weight of SLC47A1 (calculated at 62 kDa, though it may also appear at 32 and 50 kDa due to post-translational modifications) .

How can SLC47A1 antibodies be employed to investigate drug resistance mechanisms?

SLC47A1 plays a significant role in drug transport and resistance mechanisms, making antibodies against this protein valuable tools in pharmacological research:

• Platinum-based drug efficacy: SLC47A1 expression strongly correlates with the efficacy of platinum-acridine anticancer agents. Cancer cell lines with high SLC47A1 expression (e.g., HepG2, NCI-H460, MDA-MB-436) show enhanced sensitivity to these compounds at nanomolar concentrations .

• Experimental approaches:

  • Use Western blot with SLC47A1 antibodies to quantify expression levels across cell lines before drug sensitivity testing

  • Implement immunofluorescence to visualize SLC47A1 localization changes in response to drug treatments

  • Combine SLC47A1 expression analysis with functional transport assays to correlate expression with drug accumulation

• MATE1 inhibition assays: In cell lines expressing high levels of SLC47A1, pharmacological inhibition of MATE1 can significantly reduce the activity of platinum-acridine agents (up to 4000-fold lower for HepG2), confirming the transporter's role in drug efficacy .

• Biomarker potential: SLC47A1 expression serves as a potential biomarker for predicting responsiveness to certain therapies. Across the NCI-60 panel of cancer cell lines, SLC47A1 was identified as the highest positively correlated gene (among >800 scored genes) for platinum-acridine compound efficacy .

What techniques can be used to study SLC47A1's role in ferroptosis and cancer metabolism?

Recent discoveries have linked SLC47A1 to ferroptosis regulation, expanding its known biological functions:

• Lipid remodeling assays: SLC47A1 has been implicated in suppressing ferroptosis induction through lipid remodeling in pancreatic ductal adenocarcinoma cells. Researchers can use SLC47A1 antibodies to track expression changes during ferroptosis induction .

• Knockdown experiments: SLC47A1 knockdown sensitizes cells to ferroptosis in an ACSL4-SOAT1-axis dependent manner. This effect occurs through generation of polyunsaturated fatty acid-containing (PUFA) cholesterol esters .

• Metabolomic profiling: Combine SLC47A1 expression analysis using antibodies with metabolomic profiling to identify changes in lipid metabolism pathways.

• Co-immunoprecipitation: Investigate SLC47A1's interaction with other proteins involved in ferroptosis regulation using co-immunoprecipitation techniques with validated SLC47A1 antibodies.

• Functional rescue experiments: After SLC47A1 knockdown, perform rescue experiments with wild-type and mutant SLC47A1 to identify domains critical for ferroptosis regulation.

What are the optimal conditions for Western blot analysis of SLC47A1?

For successful Western blot detection of SLC47A1, consider these technical parameters:

When troubleshooting:

• If multiple bands appear, confirm specificity using blocking peptides

• For weak signal, increase antibody concentration or protein loading

• Extended exposure times may be needed for low-expressing samples

• Consider using membrane fraction enrichment for improved detection

How can SLC47A1 antibodies be used to investigate its role in drug transport and resistance?

SLC47A1/MATE1 functions as a cationic transporter influencing drug efficacy and resistance. Researchers can utilize SLC47A1 antibodies to:

• Correlation studies: Analyze SLC47A1 expression levels across diverse cell lines using Western blot, then correlate with drug sensitivity profiles. This approach identified SLC47A1 as a key predictor of cell line sensitivity to platinum-acridine derivatives in the NCI-60 panel .

• Transport mechanism investigations: Use immunofluorescence with SLC47A1 antibodies to track subcellular localization changes during drug treatments, particularly for cationic drugs.

• Expression manipulation: Combine antibody-based expression analysis with genetic manipulation (knockdown/overexpression) to establish causal relationships between SLC47A1 levels and drug response.

• Clinical sample analysis: Evaluate SLC47A1 expression in patient-derived samples using immunohistochemistry to identify potential responders to specific therapies. High SLC47A1 expression correlates with nanomolar sensitivity to platinum-acridine agents in multiple cancer types .

Research has demonstrated that SLC47A1 can facilitate rapid cellular uptake of dicationic platinum-acridine compounds, making it a potential biomarker for patient selection in clinical trials .

What emerging applications of SLC47A1 antibodies in cancer research show promise?

Several innovative research directions involving SLC47A1 antibodies are emerging:

• Biomarker development: SLC47A1 expression analysis using antibodies shows potential as a prognostic biomarker for gliomas and other cancers. High expression correlates with malignancy and poor prognosis in glioma patients .

• Drug resistance mechanisms: Investigating how SLC47A1 modulates resistance to temozolomide in glioma stem cells, with antibody-based expression analysis serving as a critical tool .

• Therapeutic targeting: Using antibodies to validate SLC47A1 as a therapeutic target, as silencing SLC47A1 influences cell viability and self-renewal activity in glioma stem cells .

• Patient stratification: Developing immunohistochemistry-based screening methods using SLC47A1 antibodies to identify patients likely to respond to specific therapies, particularly platinum-based compounds .

• Ferroptosis regulation: Exploring SLC47A1's role in ferroptosis, a form of regulated cell death involving lipid peroxidation. SLC47A1 has been linked to ferroptosis suppression through lipid remodeling .

These emerging applications highlight the expanding significance of SLC47A1 beyond its traditional role as a membrane transporter, with antibodies serving as essential tools in these investigations.

How can researchers address challenges in detecting low-abundance SLC47A1 in specific tissues?

Detection of low-abundance SLC47A1 in certain tissues presents methodological challenges that can be addressed through several strategies:

• Signal amplification techniques: Employ tyramide signal amplification (TSA) or similar methods to enhance detection sensitivity in immunohistochemistry applications.

• Sample enrichment: For Western blot applications, perform membrane fraction isolation to concentrate SLC47A1 protein before analysis.

• Alternative fixation methods: Test multiple fixation protocols when performing immunohistochemistry, as SLC47A1 epitope accessibility may vary with different fixatives.

• Optimized blocking conditions: Reduce background while preserving specific signal by testing various blocking reagents (BSA, normal serum, commercial blockers) at different concentrations.

• Enhanced imaging techniques: Utilize confocal microscopy with increased exposure settings and digital enhancement for immunofluorescence applications.

• Phosphatase/protease inhibitors: Include comprehensive inhibitor cocktails during sample preparation to prevent degradation of SLC47A1.

• Antibody combinations: Consider using cocktails of multiple validated SLC47A1 antibodies targeting different epitopes to enhance detection.

Research has successfully detected SLC47A1 in various tissues, including rat kidney, mouse brain, and rat testis using appropriate optimization techniques .

What quality control measures should be implemented when working with SLC47A1 antibodies?

To ensure reliable and reproducible results with SLC47A1 antibodies, implement these quality control measures:

• Lot-to-lot validation: Test each new antibody lot against previous lots using consistent positive control samples.

• Multiple application validation: Confirm antibody performance across different applications (Western blot, IHC, IF) when applicable to your research.

• Specificity controls: Use blocking peptides, knockdown/knockout samples, or tissues known to be negative for SLC47A1 as critical controls .

• Cross-reactivity assessment: When working with multiple species, verify species cross-reactivity experimentally rather than relying solely on manufacturer claims.

• Standardized protocols: Develop and strictly adhere to standardized protocols for each application to minimize technical variability.

• Storage and handling: Follow manufacturer recommendations for storage (-20°C is typical) and avoid repeated freeze-thaw cycles by preparing small aliquots .

• Positive controls: Include tissues with known high expression (kidney, liver) as positive controls in each experiment .